CSS LLC’s BridgeBio Pharma BBIO Stock Holding History

CSS LLC’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,481	Closed	-$164K	–	850
2024 Q2	$164K	Buy	+6,481	New	+$177K	0.01%	708

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's BBIO Position: Q3 2024 in Review

CSS LLC sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 6,481 shares — an estimated $164K sold.

CSS LLC first reported a position in BBIO in Q2 2024 and held it in 1 quarter. The position peaked at $164K in Q2 2024. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

CSS LLC reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
CSS LLC sold 6,481 BridgeBio Pharma shares in Q3 2024, an estimated $164K.
CSS LLC first reported a position in BridgeBio Pharma in Q2 2024 and held it in 1 quarter.
CSS LLC's BridgeBio Pharma position peaked at $164K in Q2 2024.
253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on CSS LLC's 13F filing for Q3 2024, filed 14 Nov 2024.